11 articles
Cabot Corporation filed a Form 4 disclosing stock transactions by CEO Sean D. Keohane for the period ending September 30. This regulatory filing details insider trading activities within the specialty
Cabot Corporation President and CEO Sean D. Keohane acquired 346 phantom stock units via the company's supplemental 401(k) plan on September 30, 2026, raising his total holdings to over 48,000 units.
Cabot Corp CEO Sean D. Keohane received 283.6 phantom stock units on September 11, 2026, bringing his total holdings to over 48,000 units, which convert to common stock upon retirement.
Cabot Corporation President and CEO Sean Keohane sold 134,895 shares worth approximately $11.4 million on August 28, 2026, following the exercise of employee stock options. He retains over 400,000 dir
Manufacturers Life Insurance Company purchased 47,211 Cabot Corporation shares worth $4.29 million, while the company reported strong quarterly earnings of $1.67 EPS and 6.4% revenue growth.
Cabot Corporation CEO Sean D. Keohane exercised 134,895 stock options at $50/share and sold them at $85/share on August 28, 2026. Post-transaction, his direct holdings total 404,134 shares.
Cabot Corp CEO Sean Keohane sold $11.4 million worth of stock after exercising options, following strong third-quarter fiscal results that exceeded analyst expectations.
Cabot Corporation insider Sean D. Keohane plans to sell 2,779 shares following a stock option exercise, succeeding a prior transaction worth approximately $7.9 million disclosed in an SEC filing.
Denali Advisors LLC reduced its Cabot Corporation holding by 18.9% in Q2, while the chemical company reported strong quarterly earnings of $1.67 EPS and 6.4% revenue growth.
Foster & Motley Inc. acquired a $1.19 million stake in specialty chemicals firm Cabot Corporation during the second quarter. While institutional investors like BlackRock increased their holdings, mixe
Cabot Corp CEO Sean D. Keohane received 83.68 phantom stock units valued at $90.82 per unit under the company's supplemental 401(k) plan, representing a compensation-related acquisition tied to common
ChemBrief